Targeted and immune-based treatments represent significant innovations in oncology and
impressively improve the prognosis of many tumor diseases. Their now widespread use as a …

Immunotherapy-induced endocrinopathies remain an adverse risk factor for patients
undergoing PD-1/PD-L1 and CTLA-4 target immunotherapy treatment. Immunotherapy …

Given the growing use of immune checkpoint inhibitor (ICI) therapy in oncology, the
prevalence of endocrine side effects is rapidly increasing. As clinicians are nowadays …

The management of cancer patients has changed due to the considerably more frequent
use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several
malignancies, improving patient survival and quality of life. Endocrinopathies have emerged …

Immune checkpoint inhibitors (ICI) have become a cornerstone in the treatment of various
human malignancies. Immune-related adverse events (irAE) are common and may affect …

The use of immunotherapies is gaining importance in the treatment of advanced
malignancies. There are many checkpoints in the immune system which prevents T-cells …

Immunotherapy in Oncology, a fundamental distinctive treatment in cancer patients, needs
molecules with different mechanisms: immune checkpoint inhibitors (ICIs) who attenuate the …

Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an
effective treatment for malignant neoplasms. However, checkpoints play a crucial role in …

The present final consensus statement of the French Society of Endocrinology lays out the
assessments that are to be systematically performed before and during anticancer treatment …